Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

322.28 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

March 23, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗

March 16, 2026

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

Via The Motley Fool

Krystal Biotech Inc (NASDAQ:KRYS) Reports Q4 2025 Earnings Beat and Key Pipeline Advancements ↗

February 17, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗

February 17, 2026

Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday.

Via Stocktwits

Topics Artificial Intelligence

Krystal Biotech (KRYS) Q4 2025 Earnings Transcript ↗

February 17, 2026

Krystal Biotech (KRYS) Q4 2025 Earnings Transcript

Via The Motley Fool

Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗

February 16, 2026

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Via The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 25, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 24, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop ↗

December 19, 2025

The timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? ↗

December 19, 2025

A sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse ↗

December 19, 2025

The stock’s collapse tells one story, but the underlying business metrics suggest a very different long-term setup.

Via The Motley Fool

Topics Regulatory Compliance

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗

November 12, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗

November 06, 2025

Via Benzinga

Krystal Biotech (KRYS) Q3 2025 Earnings Transcript ↗

November 03, 2025

Krystal Biotech (KRYS) Q3 2025 Earnings Transcript

Via The Motley Fool

Topics Earnings

Krystal Biotech (KRYS) Q3 2025 Earnings Top Estimates on Strong VYJUVEK Sales ↗

November 03, 2025

Krystal Biotech's Q3 2025 earnings crushed estimates, with EPS of $2.66 and $97.8M revenue. Strong VYJUVEK sales and global expansion in Europe and Japan drive growth.

Via Chartmill

$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗

October 31, 2025

Via Benzinga

Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts ↗

October 17, 2025

Via Benzinga

$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗

October 16, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.